LeadIQ logo
Learn more at LeadIQ.com
✕

Access Insights for Annexon Biosciences and Millions of Other Companies

Sign up for full access to Annexon Biosciences information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Insights

Cutting-edge Complement Medicines Annexon Biosciences is at the forefront of developing innovative complement medicines to treat classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Highlighting the unique mechanism and potential benefits of their product portfolio can serve as a compelling sales opportunity in the biotechnology market.

Impressive Financial Backing With recent financing of $125 million and a revenue range of $10M - $50M, Annexon showcases financial stability and growth potential. This financial backing not only instills confidence in potential investors but also presents an opportunity for sales professionals to leverage the company's strong financial position in negotiations with stakeholders.

Strategic Leadership Team Annexon's strategic hires, such as Douglas Love as President and CEO, signal a commitment to strong leadership. Leveraging the expertise and reputation of key personnel like Jamie Dananberg and Dean Artis can provide a competitive advantage in establishing rapport with clients and partners.

Diverse Product Pipeline With a diverse product pipeline including ANX005, ANX007, and ANX009, Annexon offers a range of solutions for different administration types. Understanding the unique value proposition of each product and aligning them with the specific needs of target markets can unlock various sales opportunities across multiple sectors.

Market Expansion Potential Through advancements in clinical and regulatory progress, Annexon is expanding its market reach, as seen in the progress of the ANX005 pivotal program. Identifying emerging markets or regions where there is a high demand for complement medicines, such as Guillain-Barré Syndrome, can open avenues for strategic partnerships and sales growth.

Similar companies to Annexon Biosciences

✕

Access Insights for Annexon Biosciences and Millions of Other Companies

Sign up for full access to Annexon Biosciences information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Annexon Biosciences Tech Stack

Annexon Biosciences uses 8 technology products and services including Akamai, Drupal, Google Font API, and more. Explore Annexon Biosciences's tech stack below.

  • Akamai
    Content Delivery Network
  • Drupal
    Content Management System
  • Google Font API
    Font Scripts
  • ADP
    Human Resource Management System
  • Windows Server
    Operating Systems
  • ARGUS
    Real Estate Marketing
  • Bootstrap
    UI Frameworks
  • IIS
    Web Servers

Media & News

Annexon Biosciences's Email Address Formats

Annexon Biosciences uses at least 1 format(s):
Annexon Biosciences Email FormatsExamplePercentage
FLast@annexonbio.comJDoe@annexonbio.com
90%
First.Last@annexonbio.comJohn.Doe@annexonbio.com
5%
First@annexonbio.comJohn@annexonbio.com
3%
First_Last@annexonbio.comJohn_Doe@annexonbio.com
2%

Frequently Asked Questions

Where is Annexon Biosciences's headquarters located?

Minus sign iconPlus sign iconAnnexon Biosciences's main headquarters is located at 180 Kimball Way Suite 200 South San Francisco, California 94080 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Annexon Biosciences's phone number?

Minus sign iconPlus sign icon You can contact Annexon Biosciences's main corporate office by phone at
✕

Access Insights for Annexon Biosciences and Millions of Other Companies

Sign up for full access to Annexon Biosciences information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-650-822-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Annexon Biosciences's official website and social media links?

Minus sign iconPlus sign iconAnnexon Biosciences's official website is annexonbio.com and has social profiles on LinkedIn.

How much revenue does Annexon Biosciences generate?

Minus sign iconPlus sign icon As of September 2024, Annexon Biosciences's annual revenue reached $35M.

What is Annexon Biosciences's SIC code NAICS code?

Minus sign iconPlus sign iconAnnexon Biosciences's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Annexon Biosciences have currently?

Minus sign iconPlus sign iconAs of September 2024, Annexon Biosciences has approximately 87 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Medical Officer: J. D.Chief Medical Officer: M. S.Chief Scientific Officer: R. A.. Explore Annexon Biosciences's employee directory with LeadIQ.

What industry does Annexon Biosciences belong to?

Minus sign iconPlus sign iconAnnexon Biosciences operates in the Biotechnology Research industry.

What technology does Annexon Biosciences use?

Minus sign iconPlus sign iconAnnexon Biosciences's tech stack includes AkamaiDrupalGoogle Font APIADPWindows ServerARGUSBootstrapIIS.

What is Annexon Biosciences's email format?

Minus sign iconPlus sign iconAnnexon Biosciences's email format typically follows the pattern of . Find more Annexon Biosciences email formats with LeadIQ.

How much funding has Annexon Biosciences raised to date?

Minus sign iconPlus sign icon As of September 2024, Annexon Biosciences has raised $125M in funding. The last funding round occurred on Jun 05, 2024 for $125M.

When was Annexon Biosciences founded?

Minus sign iconPlus sign iconAnnexon Biosciences was founded in 2011.
Annexon Biosciences

Annexon Biosciences

Biotechnology ResearchCalifornia, United States51-200 Employees

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

✕

Access Insights for Annexon Biosciences and Millions of Other Companies

Sign up for full access to Annexon Biosciences information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Section iconCompany Overview

Headquarters
180 Kimball Way Suite 200 South San Francisco, California 94080 US
Phone number
✕

Access Insights for Annexon Biosciences and Millions of Other Companies

Sign up for full access to Annexon Biosciences information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-650-822-****
Website
annexonbio.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2011
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $125M

    Annexon Biosciences has raised a total of $125M of funding over 8 rounds. Their latest funding round was raised on Jun 05, 2024 in the amount of $125M.

  • $10M$50M

    Annexon Biosciences's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $125M

    Annexon Biosciences has raised a total of $125M of funding over 8 rounds. Their latest funding round was raised on Jun 05, 2024 in the amount of $125M.

  • $10M$50M

    Annexon Biosciences's revenue is in the range of $10M$50M

Company Leadership

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

✕

Access Insights for Annexon Biosciences and Millions of Other Companies

Sign up for full access to Annexon Biosciences information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.